Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n = 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osime...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartmaier, Ryan J., Markovets, Aleksandra A., Ahn, Myung Ju, Sequist, Lecia V., Han, Ji-Youn, Cho, Byoung Chul, Yu, Helena A., Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong-Seok, Su, Wu-Chou, Kowalski, Dariusz M., Orlov, Sergey, Ren, Song, Frewer, Paul, Ou, Xiaoling, Cross, Darren A.E., Kurian, Nisha, Cantarini, Mireille, Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827108/
https://www.ncbi.nlm.nih.gov/pubmed/36264123
http://dx.doi.org/10.1158/2159-8290.CD-22-0586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827108/
https://www.ncbi.nlm.nih.gov/pubmed/36264123
http://dx.doi.org/10.1158/2159-8290.CD-22-0586

Ejemplares similares